Results 81 to 90 of about 15,380 (223)
Metabolic Dependencies in Pancreatic Cancer. [PDF]
, 2018 Pancreatic ductal adenocarcinoma (PDA) is a highly lethal cancer with a long-term survival rate under 10%. Available cytotoxic chemotherapies have significant side effects, and only marginal therapeutic efficacy. FDA approved drugs currently used against
Brody, Jonathan R. +3 more
core +1 more source
Advanced Materials, Volume 38, Issue 26, 8 May 2026.A novel FIRINOX‐loaded implant demonstrates controlled drug release, and potent therapeutic efficacy in pancreatic ductal adenocarcinoma mouse models with safety confirmed in a large‐animal pre‐clinical model. This innovative drug delivery platform offers a promising new treatment approach for non‐resectable, treatment‐resistant pancreatic cancer ...
Samantha J. Wade +19 more
wiley +1 more source
FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma
Therapeutic Advances in Medical Oncology, 2020 Background: Despite the scarcity of data based on randomized trials, FOLFIRINOX is widely used in the management of borderline resectable pancreatic cancer (BRPC) and locally advanced unresectable pancreatic cancer (LAPC).
Changhoon Yoo +18 more
doaj +1 more source
Modified Appleby Procedure with Arterial Reconstruction for Locally Advanced Pancreatic Adenocarcinoma: A Literature Review and Report of Three Unusual Cases. [PDF]
, 2016 BACKGROUND: Pancreatic body and tail ductal adenocarcinomas are often diagnosed with local vascular invasion of the celiac axis (CA) and its various branches. With such involvement, these tumors have traditionally been considered unresectable.
Lamb, Kathleen M. +4 more
core +1 more source
A Multidisciplinary Approach to Pancreas Cancer in 2016: A Review [PDF]
, 2017 In this article, we review our multidisciplinary approach for patients with pancreatic cancer. Specifically, we review the epidemiology, diagnosis and staging, biliary drainage techniques, selection of patients for surgery, chemotherapy, radiation ...
Agarwal, David M. +13 more
core +1 more source
Cancer Science, Volume 117, Issue 5, Page 1422-1433, May 2026.In a large real‐world C‐CAT cohort of unresectable or recurrent pancreatic cancer, we evaluated outcomes with first‐line FOLFIRINOX versus gemcitabine/nab‐paclitaxel by BRCA2 pathogenic variant and TMB status. Survival was more strongly associated with therapeutic sequencing than the initial regimen, supporting early molecular profiling to optimize the
Kazuyuki Mizuno +6 more
wiley +1 more source
A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial [PDF]
, 2015 International audienceBackground : Metastatic pancreatic adenocarcinoma (PAC) prognosis remains dismal and gemcitabine monotherapy has been the standard treatment over the last decade.
Benoist Chibaudel +7 more
core +4 more sources
Genes to Cells, Volume 31, Issue 3, May 2026.Nutrient starvation triggers pyroptosis with cleavage of pro‐IL‐18 and GSDMD in pancreatic cancer cells, and treatment of 5‐FU enhances this process. As a result, active IL‐18 is released and leads to inflammation. ABSTRACT Interleukin‐18 (IL‐18) is a pro‐inflammatory cytokine, and higher IL‐18 expression in pancreatic tumors is associated with poor ...
Hiroki Kamino +2 more
wiley +1 more source
Cell Death and DiseaseChemotherapy resistance has been a great challenge in pancreatic ductal adenocarcinoma(PDAC) treatments. Current first-line chemotherapy regimens for PDAC include gemcitabine-based regimens such as AG regimen (albumin paclitaxel and gemcitabine ...
Qinyuan Jia +15 more
doaj +1 more source
, 2015 We describe a case of metastatic pancreatic adenocarcinoma treated with neoadjuvant FOLFIRINOX chemotherapy and combined pancreatic multi-visceral and metastatic liver resection in a patient currently disease-free four years after ...
Brammer, K +3 more
core +1 more source